Participating countries


Data sources
Countries Cross sectional (N, age) Prospective (N) CVD Incidence (N) Ethnicity, Gender
a)      Australia 250 (20-30 yrs) - - Bi-ethnic, bi-gender
b)      Germany 80 (25-45 yrs) - - Europid, bi-gender
c)      Luxembourg 1432 (18-69 yrs) 1000 1432 Europid, bi-gender
d)      South Africa 1609 ( 20-65 yrs) 359 409 Bi-ethnic, bi-gender
e)     Sweden 3500 (20-60 yrs) - 3500  Europid, bi-gender
g)     Switzerland 146 (18-65 yrs) 107 (3-month
81 (12-month
- Europid, bi-gender
 Count Total N=7017  N=1547  N=5341

N=count; yrs=years; CVD=cardiovascular diseases.

Data sources for the meta-analysis will include the participating cohorts in the application phase of  the StresSed tool:

a)  Australia (Melbourne): The Alfred is a case-control cross-sectional study, including 250 individuals (20-30 years) with/without the metabolic syndrome. Participants did not receive any pharmacological treatment.

b)  Germany (Dresden): The Broken Heart Syndrome (Takotsubo) study is a case-control cross-sectional study, is completed and includes 80 individuals (25-45 years).

c)  Luxembourg: Observation of Cardiovascular Risk in Luxembourg (ORISCAV.Lux) is a prospective study (2007-2017) and includes 1432 individuals (18-69 years).

d)  South Africa (Potchefstroom): The Hypertension in Africa Research Team (2008-2017) provides a cross sectional  cohort including 1609 individuals (20-65 years).

e) South Africa (Johannesburg): The South African Breast Cancer (SABC) is a case-control cross sectional population-based study (2014-2017) and includes 500 controls (20-65 years).

g)  Sweden (Mälmo): The Malmö Offspring Study (MOS) is a prospective study of first and second generation offspring of participants from the Malmö Diet and Cancer Study (MDC). Completed (2017) and includes 3500 individuals (20-60 years).

h)  Switzerland (Bern): The Myocardial Infarction – Stress Prevention Intervention, MI-SPRINTrandomized controlled psychological prospective trial; is completed (2016) and includes 190 individuals (18-65 years).